AI Article Synopsis
- This study evaluated the impact of tislelizumab, a PD-1 inhibitor, combined with chemotherapy compared to chemotherapy alone on the health-related quality of life (HRQoL) in patients with advanced nonsquamous non-small cell lung cancer (nSQ-NSCLC).
- In a multicenter phase III trial, 332 patients were randomized to receive either tislelizumab plus platinum-pemetrexed or platinum-pemetrexed alone, with HRQoL assessed at baseline and specific weeks using validated questionnaires.
- Results showed that patients receiving the combination therapy had a significant improvement in their global health status/QoL and experienced fewer symptoms like coughing and chest pain, indicating better HRQoL compared to those receiving chemotherapy alone
Article Abstract
Purpose: This study assessed the effects of tislelizumab, a programmed cell death protein 1 inhibitor, in combination with chemotherapy versus chemotherapy alone as first-line treatment on health-related quality of life (HRQoL) in patients with advanced nonsquamous non-small cell lung cancer (nSQ-NSCLC).
Methods: Patients in this randomized, open-label, multicenter phase III study RATIONALE 304 (NCT03663205) with histologically confirmed stage IIIB/IV nSQ-NSCLC were randomized 2:1 to tislelizumab plus platinum-pemetrexed (arm T + PP) or platinum-pemetrexed alone (arm PP). Health-related QoL was measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer. Key patient-reported outcome endpoints include mean score change from baseline at weeks 12 (during chemotherapy) and 18 (following chemotherapy) in the 30-item Quality of Life Questionnaire Core's global health status/quality of life (GHS/QoL) and time to deterioration in GHS/QoL.
Results: Three hundred thirty-two patients received at least 1 dose of study drug and completed at least 1 HRQoL assessment. Global health status/QoL score improved in arm T + PP at week 18 (between-group least square mean difference, 5.7; 95% confidence interval [CI], 1.0-10.5; P = 0.018). Patients in arm T + PP experienced greater reduction in coughing (-5.9; 95% CI, -11.6 to -0.1; P = 0.044), dyspnea (-3.8; 95% CI, -7.8 to 0.1; P = 0.059), chest pain (-6.2; 95% CI, -10.8 to -1.6; P = 0.008), and peripheral neuropathy (-2.6; 95% CI, -5.5 to 0.2; P = 0.066). Median time to deterioration in GHS/QoL was not achieved for either arm.
Discussion: The addition of tislelizumab to platinum-based chemotherapy was associated with improvements in nSQ-NSCLC patients' HRQoL as well as the important disease-specific symptoms of coughing, chest pain, and dyspnea.ClinicalTrials.gov Identifier: NCT03663205.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974185 | PMC |
| http://dx.doi.org/10.1097/PPO.0000000000000583 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of population aging on quality of life and disease burden: a population-based study.
Glob Health Res Policy
January 2025
Center for Public Health and Epidemic Preparedness and Response, Peking University, Haidian District, 38Th Xueyuan Road, Beijing, 100191, China.
Background: As population aging intensifies, it becomes increasingly important to elucidate the casual relationship between aging and changes in population health. Therefore, our study proposed to develop a systematic attribution framework to comprehensively evaluate the health impacts of population aging.
Methods: We used health-adjusted life expectancy (HALE) to measure quality of life and disability-adjusted life years (DALY) to quantify the burden of disease for the population of Guangzhou.
Feasibility and preliminary efficacy of a physical activity intervention in adults with lymphoma undergoing treatment.
Pilot Feasibility Stud
January 2025
Department of Internal Medicine - Cardiology, Virginia Commonwealth University, West Hospital 8th Floor, North Wing, Richmond, VA, 23298, USA.
Background: To determine the feasibility, acceptability, and preliminary efficacy of a 6-month tailored non-linear progressive physical activity intervention (PAI) for lymphoma patients undergoing chemotherapy.
Methods: Patients newly diagnosed with lymphoma (non-Hodgkin (NHL) or Hodgkin (HL)) were randomized into the PAI or healthy living intervention (HLI) control (2:1). Feasibility was assessed by examining accrual, adherence, and retention rates.
The rise of weekly insulins: addressing the challenges of type 2 diabetes care in Brazil.
Diabetol Metab Syndr
January 2025
Serviço de Endocrinologia (SEMPR) do Hospital das Clínicas da Universidade Federal do Paraná (UFPR), Curitiba, Brazil.
Background: Type 2 diabetes mellitus (T2D) is a global health concern with a rising prevalence, particularly in Brazil. Insulin therapy plays a crucial role in managing T2D, helping to maintain glucose and energy homeostasis. Moreover, early initiation of insulin is crucial for hyperglycemic control and prevention of chronic complications.
View Article and Find Full Text PDFImpact of driver licensing renewal policies on older driver crash involvement and injury rates in 13 states, 2000-2019.
Inj Epidemiol
January 2025
Injury Prevention Research Center, University of Iowa, 145 N Riverside Dr., Iowa City, IA, 52242, USA.
Background: Motor vehicle crashes are the second leading cause of injury death among adults aged 65 and older in the U.S., second only to falls.
View Article and Find Full Text PDFTranscriptome sequencing reveals regulatory genes associated with neurogenic hearing loss.
BMC Med Genomics
January 2025
Department of Otolaryngology, First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, WuHua District, Kunming City, Yunnan Province, China.
Hearing loss is a prevalent condition with a significant impact on individuals' quality of life. However, comprehensive studies investigating the differential gene expression and regulatory mechanisms associated with hearing loss are lacking, particularly in the context of diverse patient samples. In this study, we integrated data from 10 patients across different regions, age groups, and genders, with their data retrieved from a public transcriptome database, to explore the molecular basis of hearing loss.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!